From reports that antibodies against soluble AβOs, but not monomeric Aβ, protect neural cells against the cytotoxic effects of these amyloid-β aggregates, it is feasible to theorize that antibodies capable of neutralizing AβO cytotoxicity may be beneficial in preventing and/or treating AD. Here, ABO is linked to Alzheimer disease.